Atossa Genetics (NASDAQ:ATOS) issued its earnings results on Wednesday. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.16, Fidelity Earnings reports.
Shares of ATOS stock traded up $0.01 during trading hours on Thursday, reaching $1.43. The company had a trading volume of 3,711 shares, compared to its average volume of 125,319. The business has a fifty day moving average price of $1.75 and a 200-day moving average price of $2.16. Atossa Genetics has a one year low of $0.80 and a one year high of $7.39. The firm has a market cap of $12.87 million, a PE ratio of -0.26 and a beta of 3.24.
Separately, ValuEngine cut shares of Atossa Genetics from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd.
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
Recommended Story: Put Option
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.